Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments

被引：0
|
作者：
Lucia Del Mastro
Alessandra Fabi
Mauro Mansutti
Michele De Laurentiis
Antonio Durando
Domenico Franco Merlo
Paolo Bruzzi
Ignazia La Torre
Matteo Ceccarelli
Gbenga Kazeem
Paolo Marchi
Davide Boy
Marco Venturini
Sabino De Placido
Francesco Cognetti
机构：
[1] UO Sviluppo Terapie Innovative,IRCCS AOU San Martino
[2] Regina Elena Institute, IST
[3] S. Maria della Misericordia Hospital, National Institute for Cancer Research
[4] University of Naples Federico II,Division Oncology
[5] National Cancer Institute “Fondazione Pascale”,Department Oncology
[6] A.O.O.I. Regina Margherita S. Anna,Department of Endocrinology and Molecular and Clinical Oncology
[7] UO Epidemiologia Clinica,Department of Senology, Division of Breast Oncology
[8] Medical Department,IRCCS AOU San Martino
[9] Eli Lilly UK, IST
[10] S. Cuore – Don Calabria Hospital, National Institute for Cancer Research
来源：
BMC Cancer | / 13卷
关键词：
Metastatic breast cancer; Weekly schedule; 3-weekly schedule;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma A Phase 2 Clinical Trial
    Sahai, Vaibhav
    Catalano, Paul J.
    Zalupski, Mark M.
    Lubner, Sam Joseph
    Menge, Mark R.
    Nimeiri, Halla Sayed
    Munshi, Hidayatullah G.
    Benson, Al Bowen, III
    O'Dwyer, Peter J.
    JAMA ONCOLOGY, 2018, 4 (12) : 1707 - 1712
  • [42] Zolbetuximab with gemcitabine plus nab-paclitaxel (GN) in first-line treatment of Claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
    Park, W.
    O'Reilly, E. M.
    Li, C-P.
    Oh, D-Y.
    Garcia-Carbonero, R.
    Roth, G.
    Nakajima, T.
    Moran, D.
    Yang, J.
    Li, R.
    Kunieda, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S934 - S934
  • [43] Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2-positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
    Park, Wungki
    O'Reilly, Eileen Mary
    Furuse, Junji
    Li, Chung-Pin
    Oh, Do-Youn
    Garcia-Carbonero, Rocio
    Roth, Gael
    Lee, Ho-Jin
    Kunieda, Futoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
    Cartwright, TH
    Lopez, T
    Vukelja, SJ
    Encarnacion, C
    Boehm, KA
    Asmar, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 284S - 284S
  • [45] Results of first-line weekly paclitaxel (P) plus gemcitabine (G) in metastatic breast cancer (MBC): An AERO phase II trial
    Mousseau, M.
    Serin, D.
    Petit, T.
    Priou, F.
    Zelek, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer
    Wainberg, Zev
    Hecht, J. Randolph
    CLINICAL COLORECTAL CANCER, 2006, 5 (05) : 363 - 367
  • [47] Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial
    Karthaus, Meinolf
    Poddubnaya, Irina
    Churilova, L.
    Khazanov, R.
    Veremeychuk, T.
    Rumyantzeva, E.
    Garin, M.
    Brichkova, O.
    Heinrich, Bernhard
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer
    Tiainen, Leena
    Tanner, Minna
    Lahdenpera, Outi
    Vihinen, Pia
    Jukkola, Arja
    Karihtala, Peeter
    Paunu, Niina
    Huttunen, Teppo
    Kellokumpu-Lehtinen, Pirkko-Liisa
    ANTICANCER RESEARCH, 2016, 36 (12) : 6431 - 6438
  • [49] First-line paclitaxel plus carboplatin with/without bevacizumab in recurrent or metastatic nasopharyngeal carcinoma: A multicenter, randomized, open-label, phase II trial
    Zhang, L.
    Huang, Y.
    Yang, Y.
    Ma, S.
    Lin, X.
    Lin, L.
    Zhou, T.
    Deng, Y.
    Zhang, C.
    Ding, X.
    Wang, S.
    Wang, R.
    Feng, G.
    Chen, Y.
    Xu, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
    Badwe, Rajendra
    Hawaldar, Rohini
    Nair, Nita
    Kaushik, Rucha
    Parmar, Vani
    Siddique, Shabina
    Budrukkar, Ashwini
    Mittra, Indraneel
    Gupta, Sudeep
    LANCET ONCOLOGY, 2015, 16 (13): : 1380 - 1388
12345